On September 11, 2019, Deng Hongkui research group of Basic Medicine Stem Cell Center of Peking University School, Chen Hu research group of the fifth medical center of PLA general hospital and Wu Hao research group of Beijing You 'an hospital affiliated to capital medical university collaborated on publishing research paper named “ CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia” in“ The New England Journal of Medicine”. The results of this study showed that the research team established a technical system to conduct CCR5 gene editing on human adult hematopoietic stem cells, achieved long-term stable reconstruction of the hematopoietic system in the human body. Gene editing on adult hematopoietic stem cells does not affect other tissues or reproductive systems. This work has preliminarily proved the feasibility and safety of gene-editing adult hematopoietic stem cell transplantation, which will promote the development of gene-editing technology in clinical application.

In Deng's team's latest study, a 27-year-old male patient with AIDS and acute lymphoblastic leukemia received the treatment. The results showed that adult hematopoietic stem cell gene editing technology could achieve long-term stable gene editing effect in patients, and the edited adult hematopoietic stem cells could also rebuild the human hematopoietic system for a long time. In addition, during the 19-month observation, no missed target or other side effects caused by gene editing were found, and the patient's condition was significantly improved. This is the first time that Chinese researchers have used gene editing to treat patients with AIDS and acute lymphoblastic leukemia.

Source: http://bynew.bjmu.edu.cn/zhxw/2019n/205738.htm

Time: September 12^th, 2019